Philipp O Valko1, Asim Siddique1, Claudia Linsenmeier1, Kathrin Zaugg1, Ulrike Held1, Silvia Hofer1. 1. Department of Neurology, University Hospital Zurich, Zurich, Switzerland (P.O.V., S.H.); Department of Oncology, University Hospital Zurich, Zurich, Switzerland (A.S., S.H.); Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland (C.L., K.Z.); Department of Radiation Oncology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland (K.Z.); Horten Center for Patient Oriented Research and Knowledge Transfer, University of Zurich, Zurich, Switzerland (U.H.).
Abstract
BACKGROUND: The main goal of this study was to assess frequency, clinical correlates, and independent predictors of fatigue in a homogeneous cohort of well-defined glioblastoma patients at baseline prior to combined radio-chemotherapy. METHODS: We prospectively included 65 glioblastoma patients at postsurgical baseline and assessed fatigue, sleepiness, mean bedtimes, mood disturbances, and clinical characteristics such as clinical performance status, presenting symptomatology, details on neurosurgical procedure, and tumor location and diameter as well as pharmacological treatment including antiepileptic drugs, antidepressants, and use of corticosteroids. Data on fatigue and sleepiness were measured with the Fatigue Severity Scale and the Epworth Sleepiness Scale, respectively, and compared with 130 age- and sex-matched healthy controls. RESULTS: We observed a significant correlation between fatigue and sleepiness scores in both patients (r = 0.26; P = .04) and controls (r = 0.36; P < .001). Only fatigue appeared to be more common in glioblastoma patients than in healthy controls (48% vs 11%; P < .001) but not the frequency of sleepiness (22% vs 19%; P = .43). Female sex was associated with increased fatigue frequency among glioblastoma patients but not among control participants. Multiple linear regression analyses identified depression, left-sided tumor location, and female sex as strongest associates of baseline fatigue severity. CONCLUSIONS: Our findings indicate that glioblastoma patients are frequently affected by fatigue at baseline, suggesting that factors other than those related to radio- or chemotherapy have significant impact, particularly depression and tumor localization.
BACKGROUND: The main goal of this study was to assess frequency, clinical correlates, and independent predictors of fatigue in a homogeneous cohort of well-defined glioblastomapatients at baseline prior to combined radio-chemotherapy. METHODS: We prospectively included 65 glioblastomapatients at postsurgical baseline and assessed fatigue, sleepiness, mean bedtimes, mood disturbances, and clinical characteristics such as clinical performance status, presenting symptomatology, details on neurosurgical procedure, and tumor location and diameter as well as pharmacological treatment including antiepileptic drugs, antidepressants, and use of corticosteroids. Data on fatigue and sleepiness were measured with the Fatigue Severity Scale and the Epworth Sleepiness Scale, respectively, and compared with 130 age- and sex-matched healthy controls. RESULTS: We observed a significant correlation between fatigue and sleepiness scores in both patients (r = 0.26; P = .04) and controls (r = 0.36; P < .001). Only fatigue appeared to be more common in glioblastomapatients than in healthy controls (48% vs 11%; P < .001) but not the frequency of sleepiness (22% vs 19%; P = .43). Female sex was associated with increased fatigue frequency among glioblastomapatients but not among control participants. Multiple linear regression analyses identified depression, left-sided tumor location, and female sex as strongest associates of baseline fatigue severity. CONCLUSIONS: Our findings indicate that glioblastomapatients are frequently affected by fatigue at baseline, suggesting that factors other than those related to radio- or chemotherapy have significant impact, particularly depression and tumor localization.
Authors: Martin J B Taphoorn; Roger Stupp; Corneel Coens; David Osoba; Rolf Kortmann; Martin J van den Bent; Warren Mason; René O Mirimanoff; Brigitta G Baumert; Elizabeth Eisenhauer; Peter Forsyth; Andrew Bottomley Journal: Lancet Oncol Date: 2005-12 Impact factor: 41.316
Authors: Karin Struik; Martin Klein; Jan J Heimans; Marieke F Gielissen; Gijs Bleijenberg; Martin J Taphoorn; Jaap C Reijneveld; Tjeerd J Postma Journal: J Neurooncol Date: 2008-12-09 Impact factor: 4.130
Authors: Christian R Baumann; Claudio L Bassetti; Philipp O Valko; Johannes Haybaeck; Morten Keller; Erika Clark; Reto Stocker; Markus Tolnay; Thomas E Scammell Journal: Ann Neurol Date: 2009-10 Impact factor: 10.422
Authors: Paul D Brown; Karla V Ballman; Teresa A Rummans; Matthew J Maurer; Jeff A Sloan; Bradley F Boeve; Lalit Gupta; David F Tang-Wai; Robert M Arusell; Matthew M Clark; Jan C Buckner Journal: J Neurooncol Date: 2006-02 Impact factor: 4.130
Authors: Rolf Fronczek; Sebastiaan Overeem; Sandy Y Y Lee; Ingrid M Hegeman; Johannes van Pelt; Sjoerd G van Duinen; Gert Jan Lammers; Dick F Swaab Journal: Brain Date: 2007-04-30 Impact factor: 13.501
Authors: David N Louis; Hiroko Ohgaki; Otmar D Wiestler; Webster K Cavenee; Peter C Burger; Anne Jouvet; Bernd W Scheithauer; Paul Kleihues Journal: Acta Neuropathol Date: 2007-07-06 Impact factor: 17.088
Authors: Terri S Armstrong; Allison M Bishof; Paul D Brown; Martin Klein; Martin J B Taphoorn; Christina Theodore-Oklota Journal: Neuro Oncol Date: 2016-03 Impact factor: 12.300
Authors: Jia-Shu Chen; Ross Clarke; Alexander F Haddad; Elaina J Wang; Michel Lacroix; Indra Neil Sarkar; Ramin Zand; Elizabeth S Chen; Steven A Toms Journal: J Neurooncol Date: 2022-01-04 Impact factor: 4.130
Authors: Terri S Armstrong; Marcia Y Shade; Ghislain Breton; Mark R Gilbert; Anita Mahajan; Michael E Scheurer; Elizabeth Vera; Ann M Berger Journal: Neuro Oncol Date: 2017-03-01 Impact factor: 12.300
Authors: Kevin Liaw; Rishi Sharma; Anjali Sharma; Sebastian Salazar; Santiago Appiani La Rosa; Rangaramanujam M Kannan Journal: J Control Release Date: 2020-12-05 Impact factor: 9.776